Navigation Links
Phase I Research of Extended-Release Topiramate Shows Less Fluctuation in Plasma Levels
Date:4/11/2011

he 100 mg IR topiramate administered twice daily.  USL255 also showed a lower maximum plasma concentration than IR topiramate.  

USL255 is the subject of a global Phase III clinical trial (PREVAIL), being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA), as well as an open-label extension study.

Upsher-Smith's Expanding CNS Pipeline

USL255 is the lead investigational drug in Upsher-Smith's expanding central nervous system (CNS) development pipeline, with an anticipated indication for the adjunctive treatment of adult epilepsy patients with partial onset seizures (POS).  USL's pipeline includes a number of other investigational drug programs.  Another program in this pipeline, USL261 (nasal midazolam), is under development for the management of cluster seizures in epilepsy.  Other programs include USL260 (tonabersat), an investigational drug and first-in-class neuronal gap junction modulator for the potential treatment of epilepsy.  Upsher-Smith has previously announced its partnership with Proximagen Group Plc for the PRX1 program for the symptomatic treatment of Parkinson's disease, in which Upsher-Smith is responsible for the world-wide development and commercialization of PRX1 under the direction of a joint steering committee on which there is representation of both Upsher-Smith and Proximagen.

About Epilepsy and Parkinson's Disease

Epilepsy is a medical condition that produces seizures affecting a variety of mental and physical functions.  Almost three million people in the U.S. have some form of epilepsy with about 200,000 new cases of epilepsy diagnosed each year.(1)

Parkinson's disease is a chronic, progressive neurodegenerative disease that causes impairment in motor function, as well as many non-motor complications throughout the various stages of the disease.  As many as one million people in the Uni
'/>"/>

SOURCE Upsher-Smith Laboratories
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
2. Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
3. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
4. Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results
5. Jennerex and Transgene Announce Presentation of Phase 1 Data Demonstrating that JX-594 Administration Targets Tumor Vasculature
6. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
7. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
8. Positive Phase 2 Results Reported with Boehringer Ingelheims Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
9. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
10. Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
11. Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013   Polymer Technology Systems, Inc. ... Group to integrate the CardioChek ® ... by health systems across the country. The CardioChek ... distributed through Hanson Medical Systems , offers ... LDL cholesterol, triglycerides, and glucose. (Logo: ...
(Date:6/17/2013)... , June 17, 2013  Hanger, Inc. (NYSE: ... credit agreement that increases its senior secured facilities to ... million previously.  The new credit agreement includes a $200 ... loan facility.  The previous credit agreement was comprised of ... million term loan.  Each new facility matures on June ...
(Date:6/17/2013)... 2013 BioMed Realty Trust, Inc. (NYSE: ... declared a second quarter 2013 dividend of $0.235 per share ... dividend of $0.94 per common share. The ... stockholders of record at the close of business on June ... BioMed Realty delivers optimal real estate solutions for biotechnology ...
Breaking Medicine Technology:Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 2Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 3BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 3
(Date:6/18/2013)... June 18, 2013 Parker Waichman ... the rights of victims injured by defective medical devices, ... of Medtronic’s Infuse bone graft products are now available. ... medical journal, the two studies serve up two key ... when comparing Infuse and the traditional bone graft; and ...
(Date:6/18/2013)... June 18, 2013 Sun Buick GMC, Moosic, ... Health Services 20th Annual Golf Tournament on Thursday, June 20, ... hole-in-one prize is a 2013 Buick Verano and will go ... a hole-in-one on Irem’s 7th hole. , The MFHS golf ... is a four person captain and crew team for 18 ...
(Date:6/18/2013)... developed at Case Western Reserve University,s College of ... has made available avatarsvirtual patientsto train speech-language pathologists. ... training to evaluate speech-language disorders to practice using ... trainee, because a diagnosis doesn,t have to be ... students studying to become speech-language pathologists have previously ...
(Date:6/18/2013)... myCNAjobs announces the addition of new resources to ... to the Caregiver Resources Center. , As more caregivers ... baby boomers each day, the need for caregiver ... has never been greater. myCNAjobs, the fastest growing ... the first-ever free resource center for caregivers seeking professional ...
(Date:6/18/2013)... New York, New York (PRWEB) June 18, 2013 ... forward in both state and federal court, a new report ... of more than 70,000 U.S. Food & Drug Administration (FDA) ... According to NewsChannel5 in Cleveland, Ohio, over 4.700 Mirena ... since 2008, while more than 1,300 have reportedly experienced uterine ...
Breaking Medicine News(10 mins):Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 3Health News:SimuCase avatars advance speech-language pathology training 2Health News:myCNAjobs Adds New Resources to Growing Caregiver Career Center 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 3
... manipulation of inheritable genes to enable people to produce ... family relationships and on being human, warns a leading ... diseases hold out great hope for IGM technology, which ... as Huntington’s Disease and schizophrenia on to their children.// ...
... the risk of pancreatic cancer in both sexes,while moderate ... obese individuals,says Dr. Dominique S. Michaud the head ... National Cancer Institute in Rockville, Maryland and colleagues collected ... 75 years of age, who participated in the Health ...
... itself by growing new cells after a heart attack. This surprising ... Piero Anversa and colleagues of the New York Medical College in ... divide after a heart attack.// , ... died within a few days of having a heart attack and ...
... According to researchers, patients suffering from Angina may have ... doses of antibiotics. Angina, a common cardiovascular disorder affecting ... chest pain caused by blood vessels too clogged to ... Current treatment involves either medication or for more serious ...
... week could significantly increase the success rate of pig-to-human ... indicated that rejection of animal cells and organs by ... presence of the gene alpha 1,3 galactosyl transferase. The ... to the surface of pig cells, flagging them up ...
... technique to keeping heart arteries flowing easily after angioplasty ... major weakness of the common procedure.Doctors released the ... drug-coated stent. In testing on 30 patients over three ... an accomplishment almost unheard of in medicine.// ,More ...
Cached Medicine News:Health News:Perfect babies boon or a bane? 2Health News:Antibiotic, Gene Therapy Help Treat Angina 2Health News:Antibiotic, Gene Therapy Help Treat Angina 3Health News:Xenotransplantation “breakthrough” 2Health News:A ray of hope in Angioplasty dilemma 2
... The ACS:180 SE is ... ACS:180 PLUS, consisting of important ... further simplify routine operation and ... represents the "Next Generation" ACS:180. ...
... Chrono-log's wide range of Platelet aggregometers ... to meet particular needs. Single, dual ... with chart recorder outputs or digital ... Chrono-log Optical aggregometers, which measure platelet ...
... Platelet aggregometers allows to choose the ... Single, dual and four sample units ... or digital computer outputs. In addition ... measure platelet aggregation in platelet-rich-plasma (PRP), ...
... The PAP-4 is a four channel Platelet ... available: von willebrand assay (Ristocetin cofactor), platelet ... also be used for the evaluation and ... channels allow four tests to be run ...
Medicine Products: